Tous Actualités
Suivre
Abonner Intercell AG

Intercell AG

Intercell-Novartis Vaccine alliance - Intercell receives next EUR 40 million payment

Wien (euro adhoc) -

» EUR 40 m further option fee paid by Novartis
» Actual cash position more than EUR 200 m
» Development of key products within the Novartis alliance 
  progressing
  ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
  the content of this announcement.
cooperations
Vienna (Austria), September 25, 2008 - Intercell
AG announced the completion of the next step in implementing the 
strategic alliance with Novartis which was initiated in July 2007. A 
EUR 40 m option fee agreed with Novartis was received by Intercell 
today. Together with the EUR 150 m equity investment made in 
September 2007 and the EUR 80 m option fee and upfront licence fee 
paid in November 2007, the payment brings the cash received to date 
by Intercell under its strategic alliance with Novartis to a total of
EUR 270 m.
"After the payment of all costs associated with the recently 
completed acquisition of IOMAI Corporation, Intercell's cash position
is now more than EUR 200 m. We also expect our cash position by the 
end of 2008 to be around EUR 200 m. This secures the optimal speed of
all development programs and the strategic growth of the company", 
states Werner Lanthaler, CFO of Intercell.
About the Intercell-Novartis cooperation
In July 2007, Intercell and Novartis signed a major strategic 
partnership to accelerate innovation in the development of vaccines 
against infectious diseases. The partnership grants Novartis option 
rights to future vaccine candidates discovered by Intercell during 
the long-term collaboration.
About Intercell AG
Intercell AG is a growing biotechnology company that designs and 
develops novel vaccines for the prevention and treatment of 
infectious diseases with substantial unmet medical needs. The 
Company's technology platforms include an antigen-discovery system, 
two proprietary adjuvants and a novel patch-based delivery system. 
Based on these technologies, Intercell has strategic partnerships 
with a number of global pharmaceutical companies, including Novartis,
Merck & Co., Inc., Wyeth, Sanofi Pasteur, Kirin and the Statens Serum
Institut. The Company's lead product is a vaccine against Japanese 
Encephalitis. That vaccine successfully concluded pivotal Phase III 
clinical trials in 2006, and Intercell is seeking marketing approval 
in the United States, Europe and Canada. Approval in those markets is
anticipated during the second half of 2008. The Company's development
pipeline includes Phase II vaccine programs for Pseudomonas (in-house
development) and S. aureus, which is being developed with Merck & Co.
Inc. The Company's novel Travelers' Diarrhea vaccine patch will enter
Phase III testing in 2009. Intercell is also in clinical trials of a 
vaccine enhancement patch with injected pandemic influenza vaccines 
(one shot plus patch). In addition, five other products focused on 
infectious diseases are in preclinical development. Intercell is 
listed on the Vienna stock exchange under the symbol "ICLL". For more
information, please visit: www.intercell.com
end of announcement                               euro adhoc

Further inquiry note:

Intercell AG
Lucia Malfent
Head of Corporate Communications
Tel. +43 1 20620-1303
lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wiener Börse AG / official market

Plus de actualités: Intercell AG
Plus de actualités: Intercell AG